ApniCure: Unmasking Sleep Therapy With An Alternative To CPAP

Sleep apnea is now widely recognized as an underlying factor for major CV diseases and metabolic disorders, making it a huge market opportunity. ApniCure hopes that by avoiding the CPAP masks that patients hate while using the differential pressure therapy that doctors and payors like, it can unlock this potential blockbuster market.

Sleep medicine is a relatively recent clinical specialty, yet obstructive sleep apnea (OSA) – the most prevalent sleep disorder – has long been one of the most vexing clinical challenges facing the medical device industry. The science of sleep medicine has grown exponentially over the last 30 years, producing groundbreaking research revealing the extent to which sleep disorders have a significant impact on a multitude of serious cardiovascular diseases and metabolic disorders. The state of sleep therapy, however, has remained largely stagnant. The most effective therapy continues to be what it was in 1981 when CPAP (continuous positive airway pressure) was invented. Unfortunately, CPAP remains almost as unpopular with patients today as it was then, mainly because it requires patients to wear cumbersome, uncomfortable facial masks while sleeping.

As a result, while the OSA population continues to increase as a result of both improvements in diagnosis and the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Innovation

The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic

 
• By 

Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.

Johnson & Johnson MedTech: How To Scale Digital Solutions

 

J&J's EMEA head of digital solutions, Julia Fishman, talks about the hurdles in scaling digital innovation and what’s up next on J&J’s innovation road map. Robot-assisted surgery pioneer Ivo Broeders gives his perspective on the difficulties in clinical adoption.

How Ethris Cracked mRNA’s “Do Not Shake” Problem To Unlock Respiratory Therapeutics

 
• By 

A German biotech has solved a fundamental physics problem that has limited mRNA therapeutics to injectable vaccines. Its breakthrough stabilizer technology allows mRNA particles to survive the mechanical stress of inhalation delivery, opening the door to treating chronic respiratory diseases.

Finding The Fire: AltruBio’s Novel Approach To Autoimmune Disease

 
• By 

CEO Judy Chou brings big pharma experience to tackle chronic inflammation with the company's first-in-class PSGL-1 targeting therapy.

More from In Vivo

Deals Shaping The Industry, May 2025

 
• By 

An interactive look at pharma, medtech and diagnostics deals made during May 2025. Data courtesy of Biomedtracker.

Podcast: Flagship’s Vision To Predict And Prevent Illness, With Raj Panjabi

 
• By 

Flagship Pioneering senior partner Raj Panjabi discusses shifting health care from reactive treatment to AI-powered prediction and prevention of disease before symptoms emerge.

Rising Leaders 2025: Namrata Saroj On The Importance Of Authenticity In Ophthalmology

 

Namrata Saroj, chief business officer of Ocular Therapeutix, is highly respected in the retina community for her contributions to drug development. She talked to In Vivo about her journey in ophthalmology, leadership philosophy and the importance of authenticity in a close-knit specialty.